<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-30B5J4ZT</identifier><date>2014</date><creator>Locatelli, Igor</creator><relation>documents/doc/3/URN_NBN_SI_doc-30B5J4ZT_001.pdf</relation><relation>documents/doc/3/URN_NBN_SI_doc-30B5J4ZT_001.txt</relation><format format_type="issue">1</format><format format_type="volume">65</format><format format_type="type">article</format><format format_type="extent">str. 24-30</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">3605361</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-30B5J4ZT</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antidepresivi</subject><subject language_type_id="slv">antipsihotiki</subject><subject language_type_id="slv">farmakodinamika</subject><subject language_type_id="slv">farmakokinetika</subject><subject language_type_id="slv">genotipizacija CYP2D6</subject><subject language_type_id="eng">risperidon</subject><title>Influence of pharmacokinetic properties of antidepressants and antipsychotics on their clinical effects</title><title>Pomen farmakokinetike pri napovedovanju kliničnih učinkov antidepresivov in antipsihotikov</title></Record>